Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?

Benzer Materyaller

• Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms
  Yazar:: Raucci, Federica, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• In-depth immunophenotyping data relating to IL-17Ab modulation of circulating Treg/Th17 cells and of in situ infiltrated inflammatory monocytes in the onset of gouty inflammation
  Yazar:: Raucci, Federica, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Present Status and Future Trends of Natural-Derived Compounds Targeting T Helper (Th) 17 and Microsomal Prostaglandin E Synthase-1 (mPGES-1) as Alternative Therapies for Autoimmune and Inflammatory-Based Diseases
  Yazar:: Saviano, Anella, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Repetitive Exposure of IL-17 Into the Murine Air Pouch Favors the Recruitment of Inflammatory Monocytes and the Release of IL-16 and TREM-1 in the Inflammatory Fluids
  Yazar:: Maione, Francesco, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Interleukin-17A (IL-17A): A silent amplifier of COVID-19
  Yazar:: Maione, Francesco, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)